Nuo Therapeutics AURX

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing products for chronic wound care primarily within the United States. The company commercializes innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its core offering is a point-of-care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market.

Nuo Therapeutics generates revenue primarily through the sale of its Autologous Platelet-Rich Plasma (PRP) gel, marketed under the brand name Aurix®. Revenue is derived from direct sales of the Aurix System to healthcare providers and from distribution agreements, including the agreement with Smith+Nephew under which the company supplies a private label version of its product. The company also earns revenue from upfront fees, milestone payments, and ongoing royalties associated with its distribution partnerships.

The company operates through the following segments:

• Autologous Blood Separation and Therapy: This segment focuses on the development, manufacturing, and commercialization of the Aurix System, which separates a patient’s own blood to produce a platelet-rich plasma gel for wound healing. The Aurix System includes proprietary devices and disposable kits used at the point of care to generate the therapeutic gel. The Aurix® brand and trademark are central to this segment, representing the company’s FDA-cleared product for chronic wound management.
• Distribution and Partnership Services: This segment encompasses revenue and activities related to strategic distribution agreements, including the partnership with Smith+Nephew. Under this segment, Nuo Therapeutics manufactures and supplies private label Aurix products to its partners and earns fees for technology transfer, regulatory support, and market access. The segment also includes revenue from upfront payments, milestone achievements, and ongoing royalties tied to collaborative agreements.

Nuo Therapeutics occupies a niche position in the advanced wound care market, which includes advanced dressings, devices, and biologics. The company competes with larger medical device firms and specialized biologics providers but differentiates itself through its autologous, point-of-care approach that uses the patient’s own blood to stimulate healing. Its competitive advantage lies in the proprietary nature of the Aurix System, its FDA clearance, and the clinical evidence supporting its efficacy in treating diabetic foot ulcers and other exuding wounds.

Nuo Therapeutics serves healthcare providers treating patients with chronic wounds, including hospitals, outpatient clinics, and physician offices. The company’s customers include wound care centers, long-term care facilities, and independent medical practitioners focused on diabetic foot ulcers, pressure ulcers, and leg ulcers. Specific customer names are not disclosed in the filing, but the company references relationships with more than 200 third-party sales agents and distributors as of March 31, 2026.